IRIS
PUPPO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 14.682
Totale 14.682
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 14.682
Totale 14.682
Salva come PNG Salva come JPEG
Città #
Genova 12.123
Rapallo 1.549
Genoa 968
Bordighera 42
Totale 14.682
Salva come PNG Salva come JPEG
Nome #
Infection risk associated with anti-TNF-α agents: A review 164
Possible differences in the mechanism(s) of action of different glucocorticoid hormone compounds. 156
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer 144
Vaccine-preventable infections in Systemic Lupus Erythematosus 140
S-adenosil-L-methionine is able to reverse the immunosuppressive effects of chenodeoxycholic acid in vitro. 136
The antiphospholipid syndrome: from pathophysiology to treatment 135
Improvement in esophageal motor abnormalities in systemic sclerosis patients treated with cyclosporine: comment on the article by Clements et al. 133
Soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis 132
TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis 132
Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis 131
Autoimmune intrahepatic cholangiopathy associated with antiphospholipid antibody syndrome 129
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. 129
Immunogenicity of infliximab and adalimumab: What is its role in hypersensitivity and modulation of therapeutic efficacy and safety? 129
Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro 128
Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications 128
Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response? 125
Soluble HLA-G molecule in patients with perennial allergic rhinitis. 125
Soluble serum HLA-G and HLA-A, -B, -C molecules in patients with seasonal allergic rhinitis exposed to pollens. 124
Immunoregulatory Role of HLA-G in Allergic Diseases 123
Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. 122
General surgery, translational lymphology and lymphatic surgery 121
Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. 120
Blunted coronary flow reserve in systemic sclerosis: a sign of cardiac involvement in asymptomatic patients 120
Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy 119
Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients 119
Plicometer skin test: a new technique for the evaluation of cutaneous involvement in systemic sclerosis. 117
Increased beta2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. 116
In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion? 115
Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes 115
Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events 114
Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis. 112
Fas, Fas ligand, and transfusion immunomodulation 112
Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus 112
Soluble HLA class I and Fas ligand molecules in blood components and their role in the immunomodulatory effects of blood transfusions. 111
Immune cell circulating subsets are affected by gonadal function. 111
Effect of levamisole on postoperative immunosuppression 111
Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: correlation with clinical outcome 111
Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients 111
Potential use of TNF-α inhibitors in systemic sclerosis. 111
Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. 110
Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction 110
Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors. 110
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 110
Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: A prospective, observational cohort 110
Immunoglobulin production pattern is allergen-specific in polysensitized patients. 108
Current views on diagnostic approach and treatment of lymphedema 107
Deficiency of the autologous mixed lymphocyte reactions of non-T/T and T/T type in intravenous drug abusers infected by the human immunodeficiency virus (HIV). 106
Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. 106
Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis 105
Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis 104
Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients. 104
Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis 102
Serum HLA class I antigens: markers and modulators of an immune response? 101
New glucocorticoids. Mechanisms of immunological activity at the cellular level and in the clinical setting. 101
Immune homeostasis requires several biologic factors including glucocorticoid hormones 101
Serum zinc levels in patients with multiple myeloma ad waldenstrom's disease 100
dsDNA-, nucleohistone- and DNASE I-reactive T lymphocytes in patients affected by systemic lupus erythematosus: correlation with clinical disease activity. 100
Immunohistochemical evidnce of HLA-G expression in extravillous trophoblast invading decidual tissues. 100
Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity. 100
Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer. 100
null 99
Defective expression and function of the leukocyte associated ig-like receptor 1 in B lymphocytes from systemic lupus erythematosus patients 99
The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases 98
Efficacy and safety of etanercept in chronic immune-mediated disease. 98
Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). 98
Anti-tumour necrosis factor-a treatment with infliximab for disseminated granuloma annulare 96
Remission of Brucella endocarditis in a patient with mitral valve mechanical prosthesis by antibiotic therapy alone: a case report 96
Apoptosis in the Homeostasis of the Immune System and in Human Immune Mediated Diseases 95
DsDNA-specific T-cell lines in systemic lupus erythematosus patients: data suggesting their oligoclonality. 95
Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy 95
Genetic factors and systemic sclerosis 95
Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. 94
Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. 94
Immune regulatory properties of corticosteroids: prednisone induces apoptosis of human T lymphocytes following the CD3 down-regulation. 94
Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. 94
CD4+ Th0 cell clones, isolated from a metastatic lymph node of a melanoma patient, possess cytolytic function. 94
Update upon efficacy and safety of TNF-α inhibitors. 94
FRI0199 EFFECTIVENESS AND SAFETY OF BELIMUMAB IN PATIENTSWITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC STUDY 94
Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily 93
Increased serum concentration of soluble HLA-DR antigens in HIV infection and following transplantation. 93
Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. 93
Decreased lymphocyte blastogenesis, IL2 production and NK activity following nifedipine administration to healthy humans. 92
Lymphatic microsurgery to treat lymphedema: techniques and indications for better results. 92
null 92
Recurrent intestinal perforation associated with thrombosis of inferior vena cava: uncommon presentation of antiphospholipid syndrome. 92
Soluble HLA-G serum levels in patients with the Acquired Immunodeficiency Syndrome affected by different AIDS-defining conditions before and after anti-retroviral treatment 91
Endothelial dysfunction in rheumatic autoimmune diseases. 91
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study 91
Soluble HLA antigens: new roles and uses 90
Emerging biologic drugs for the treatment of rheumatoid arthritis 89
An Uncommon Presentation of Pancreatic Carcinoma 89
Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis 88
Current recommendation to reduce the burden of bacterial and viral infections in patients affected by systemic lupus erythematosus 88
Update upon the infection risk in patients receiving TNF alpha inhibitors 88
Nocturia: an uncommon presentation of lower-limb lymphedema. 87
null 87
Selective TNF-α inhibitor-induced injection site reactions. 86
null 86
Double-stranded deoxyribonucleic acid binds to HLA class II molecules and inhibits HLA class II-mediated antigen presentation. 86
HLA-G Expressing Immune Cells in Immune Mediated Diseases 86
Totale 10.730
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.882
article - articoli 38.798
book - libri 322
conference - conferenze 337
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 425
Totale 79.764
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019691 0 0 0 0 0 0 0 0 0 0 379 312
2019/20204.327 176 122 205 285 392 504 673 306 360 710 461 133
2020/20211.307 77 130 122 161 75 134 77 102 100 130 82 117
2021/20222.013 60 166 134 238 60 128 121 479 90 181 100 256
2022/20231.840 167 109 31 188 319 331 2 143 313 13 198 26
2023/2024735 33 162 13 107 64 146 79 71 52 8 0 0
Totale 14.933